Search Index

Discussing an upcoming biotech thriller book Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link ‘The Molecule’ by Dr Rick Sax and Dr Marta New Last updated: 02/01/26, 18:11 Published: 08/01/26, 08:00 Discussing an upcoming biotech thriller book Science, to some extent, is very black and white. You carry out experiments; you analyse the data, and you could use numerous techniques to get results. Although there is a range of techniques you could use to analyse and interpret the data, if it has been carried out correctly, the results should be reproducible. 1 + 1 will always equal 2, a eukaryote will always have a nucleus, and pure water will always have a boiling point of 100ºC. Once again, science is entirely black and white. But after an hour of conversation on a cold London afternoon, this writer can conclude that the life of a scientist does not have to be as black and white as their research. This is confirmed by looking at the fascinating lives of Dr Marta New and Dr Rick Sax. Dr Marta New Dr. Marta New's career spans the intersection of science and business, beginning with her PhD in Microbiology and Immunology from the University of Illinois Chicago. Demonstrating her versatility, she pursued an MBA at Northwestern University's Kellogg School of Management just two years later. Recognizing her passion extended beyond academia, Dr. New ventured into the business world, where she has held various influential roles. Her career includes positions as a venture capitalist at ARCH Venture Partners, board observer for numerous biotech companies, and strategic advisor to pharmaceutical firms. Dr. New's expertise lies in translating scientific breakthroughs into viable business opportunities, particularly in the areas of drug discovery and development. Currently, she is the founder and CEO of Radyus Research, a company focused on accelerating drug discovery through innovative AI-powered platforms. In this role, Dr. New continues to drive innovation and strategic growth in the biotech and pharmaceutical sectors, leveraging her unique blend of scientific knowledge and business acumen. Dr Rick Sax Dr. Rick Sax is a distinguished figure in the pharmaceutical industry with over 30 years of experience in senior leadership positions. His career spans across major pharmaceutical companies, including Merck & Co. and AstraZeneca, where he held executive roles in clinical development. At Merck, Dr. Sax led cardiovascular drug development and served on key business strategy teams. At AstraZeneca, he took on various leadership positions, including Vice President for U.S. Clinical Research and roles in global Medical Sciences. Dr. Sax later joined Quintiles (IQVIA) as Senior Vice President for Integrated Clinical Services, where he played a crucial role in developing innovative approaches to clinical program design and drug development strategies. His expertise encompasses drug research and development, clinical program design, translational medicine, and the application of information technology in clinical research. Currently, Dr. Sax serves as an advisor to biotechnology startups and consulting firms, leveraging his extensive experience to improve pharmaceutical R&D efficiency and productivity. Through their amazing expertise they have joined hands to write a biotech thriller called the ‘The Molecule’. What is the inspiration behind the novel The Molecule ? Science thrives on curiosity, discovery, and the pursuit of knowledge, often driven by a passion to understand the unknown. On the other hand, business is fueled by profit, efficiency, and the drive to deliver tangible results in the shortest possible time. The challenges can be immense in the biotech industry, where these two worlds must collide. Transforming a scientific breakthrough into a marketable product requires more than just innovation; it demands strategic thinking, financial acumen, and a deep understanding of the regulatory environment. The journey from lab bench to market shelf is fraught with obstacles, including securing funding, navigating complex regulations, and managing stakeholders' expectations with very different goals. In their new novel, The Molecule , authors Rick Sax and Marta New delve into the intricate world of drug development, breaking the conventional notion that this process is solely the domain of academia. The book explores the multifaceted journey of a startup company navigating the complex path of science, regulation, and industry. When asked about the inspiration behind the book, Rick and Marta emphasised their desire to shed light on the complex interplay between scientific innovation and the financial forces that drive it. They wanted to illustrate that drug development is a scientific endeavour and a battleground where researchers, regulators, and industry professionals often find themselves at odds. While The Molecule is a work of fiction, it brings a deep emotional resonance. The authors were keen to portray the technical challenges of developing a new drug and the human element—the hopes, fears, and sacrifices of those involved. Rick and Marta crafted a narrative that captures the struggles and triumphs, emphasising the complex journey of bringing a new drug to market. The book goes beyond the laboratory, vividly depicting the stages a startup company must navigate to succeed. It paints a realistic picture of the hurdles and setbacks often encountered along the way, making it a compelling read for anyone interested in the intersection of science, business, and human emotion. This biotech thriller also serves as a reminder that the fusion of science and business, though complex, is essential for driving progress and bringing life-changing innovations to the world. What is the drug development process, and what are the challenges? As mentioned, drug development is a long, arduous, and multifaceted journey. A journey that, in reality, is not limited to academia or clinical research. We must remember that drug development translates an idea into a drug in the market, a process that spans more than simple laboratory experiments. The book The Molecule gives us a glimpse of this process. As it turns out, there is a lot more that happens even before clinical trials begin. Unsurprisingly, the process of drug development began before "development". Instead, it starts as drug "discovery". Here, scientists wear their thinking hats to try and understand a disease, hoping to discover new insights or technologies that provide an approach to treatment. As Marta neatly outlined, scientists at this stage are surrounded by numerous questions, such as the drug's mechanism of action, how it works, etc. However, this discovery is not a finished product but rather a technology. Different questions must be asked to translate a fresh-off-the-lab technology into a marketable drug. Namely, "Is it safe and is it efficacious?" Next, the drug development journey will continue into the preclinical stage. Those who work in preclinical drug development may be familiar with the abundance of cell cultures and animal models used in this stage. Indeed, the preclinical stage often follows either or both in vitro and in vivo testing. Marta also highlighted another key factor, reproducibility. Crucially, a reproducible study refers to a repeated study done under different conditions or parameters and by other researchers where the results or analyses are the same or in agreement. Any study can be vulnerable to biases. Therefore, a reproducible study ensures fair, correct, and trustworthy results that allow scientists the confidence that the drug is safe before it enters clinical trials. Furthermore, testing the potential drug with a "standard of care" is equally essential. This means testing the candidate against an existing drug for the same disease. The process seeks to observe efficacy, whether the experimental drug is more efficacious than an already marketed drug. In other words, if the drug is working. As you can see, much work must be done before drug development reaches human testing. Preclinical studies may vary in size, but they are crucial in defining how safe the drug is before it is tested on people. Therefore, Rick and Marta emphasise that the preclinical stage must follow good practice and the correct guidelines, collecting data to paint a detailed pict ure before being given to the regulatory bodies. Upon the success of preclinical research and the approval of human testing by the regulatory bodies, a process that can take up to 5 years, we finally arrive at clinical trials. In short, clinical trials will further test the candidate drug on human subjects for safety and efficacy, dosage, side effects, and adverse reactions. As the trial progresses, the group size of each phase also increases, and as the number of human subjects increases, so does the cost. Rick and Marta explained that labs or smaller companies will usually carry out the preclinical research, but will search for larger pharmaceutical companies as partners to continue clinical trials. The drug development process is complex and concerns a multidisciplinary team of scientists, corporate partners, and regulatory bodies. However, this process is necessary to create a safe and effective drug that can change lives. Many science and STEM students gravitate only towards science and their respective passionate fields and, unfortunately, tend to find business intimidating. So, what would be your advice for these students to begin learning more about the business side of STEM and building their own start-up? The ideal way to answer this question is to consider it in two different parts: exploring a new passion (the world of business) and the advice to learn more. In many ways, one may always feel the vulnerability of exploring the unknown. Perhaps that is why we live following our passions: there is a certain security in their reliability and certainty for enjoyment and happiness. A safety blanket, so to speak. However, this very blanket could be the culprit that slowly suffocates all possibilities of growth, keeping you safe, secure, and immovable. By reading through their novel, The Molecule , and doing a Google search of these two writers' incredible lives, any reader can surely understand how to grow in pharmacology; there needs to be a specific element of business. Of course, for many, the thought of entering the clutches of the world of business, a world of numbers, negotiations, and a lack of laboratory equipment and sterilisation, might seem daunting. However, it is essential for any reader to understand that if they wish to enter the world of drug development, they will not find this door in academia. Instead, the key to drug development is built when different skill sets, areas of knowledge, and technical expertise come together through the work of a multipurpose team. This delicate and intricate process centres on the team, a team that requires multiple disciplines to work in harmony and in an environment where creativity may flourish. However, how can one go from understanding the importance of business in drug development to taking the first steps into this new, terrifying, and exhilarating world? The simple answer to this is explored in The Molecule . To succeed in the unknown, one must find a good mentor. Someone you truly believe in to show you the way. Of course, there should always be some caution in ensuring the right mentor is found. However, this should not hinder any keen reader from trying, as every experience can be an opportunity for growth. Furthermore, there are many positive stories of successful mentorships, as seen through Dr Sax’s personal experience. In the beginning, like many in STEM, he considered pharmacology “the dark side”. At the time, he worked at Cornell University Medical Centre, living the life many could only dream of. He spent his days working as a triple blend between a physician, a researcher, and a teacher – his passions. When first approached by a mentor on the possibility of pharmacology, a scene was conjured. A scene that showed the fiery pits of hell with the personification of pharmacology itself as a fearful villain pushing one into damnation. However, the support and encouragement from this mentor were the tiny pushes that convinced him to try, leading him to where he is today. There are many ways to find these mentors. Through academia, students can take advantage of programs such as hosting entrepreneurial activities, wet labs, organised panels, and events, such as “speak to a member of the industry”. Even exploring master programs in drug development could be a step forward in matching a student with potential mentors. Moreover, outside of the academic halls, there are many opportunities to form connections. By browsing LinkedIn groups, forums, and Reddit posts, you can find your people and see their steps. Following Dr. New’s humbling words, “It is important for students to remember they are not the first in the history of civilisation to think of entrepreneurship, and it is online where they can find signatures of the work others have done". "Your people" will be the ones that share your confusion, fear, perhaps lack of expertise, love for adrenaline, and a good challenge. Once you find them, everything will start flowing. Furthermore, consider how the real world works: if you want something, you need to go get it, be it with cold reach outs into the unknown and follow-up emails. On average, it takes 6 follow-up emails until someone replies to you. Hence, whatever you are doing, selling, or asking, do it 6 times before you give up. What vision do you see for the future of the biotechnology industry? When posed this question, both Fredrick and Marta conveyed that the future of biotechnology is heavily unpredictable, primarily due to the variability in the success of biotech startups. Moreover, one significant factor influencing this unpredictability is the funding which these firms receive. However, the changes in focus to new trends in biotechnology show great promise for how this large industry may grow and develop. For instance, a new trend is the considerable focus on rare diseases and targeted therapies for specific mutations such as the ALMK-14 mutation in lung cancer. There is also a significant focus on looking at disease subcategories and honing in on the specific type of disease. For example, instead of broadly targeting lung cancer, there is a trend towards addressing specific forms such as small cell lung cancer and non-small cell lung cancer. This precise approach aims to focus on specific characteristics of each disease’s subtype, for example, some forms of lung cancer may be more aggressive than others. Moreover, both Marta and Richard both highlighted the intertwining of biotechnology with other fields, specifically artificial intelligence (AI). An interesting example of this is utilising AI to develop targeted therapies for molecular markers of disease which may have been identified by lab techniques such as Next Generation Sequencing (NGS). Finally, the industry encompasses a wide range of professions from smaller pharmaceutical companies to larger pharmaceutical firms each with different focuses. Due to these varied focuses, the industry will likely develop and progress in diverse ways, reflecting the various aims of these firms. This diversity further reinforces the unpredictability of the industry’s future but also makes it an interesting field to watch. A massive thank you to Nick Johnstone for giving Scientia News this opportunity; it means a lot. We have learnt so many new things and it has been very inspiring talking to Rick and Marta. For more information, visit the following hyperlinks: Dr Rick Sax ( research ) Dr Marta New Nick Johnstone ( author ) Written by Inês Couto André, Jeevana Thavarajah, Stephanus Steven & Harene Elayathamby Related book reviews: Intern Blue , The Emperor of All Maladies Project Gallery

Dive into the latest biological research! Explore the profound impact of negligent exercise on well-being, discover breakthroughs in organoid and iPSC research, and gain insights into how biomarkers are enabling disease diagnosis and prevention- along with public health news. Biology Articles Dive into the latest biological research! Explore the profound impact of negligent exercise on well-being, discover breakthroughs in organoid and iPSC research, and gain insights into how biomarkers are enabling disease diagnosis and prevention- along with public health news. You may also like: Cancer , Ecology , Genetics , Immunology , Neuroscience , Zoology , and Medicine Can a human brain be uploaded to a computer? Uncovering the possibilities of transferring information from your brain to a computer Impacts of negligent exercise on physiology How to avoid negligent personal training as it can harm the individual Key historical events in public health A timeline of discoveries in the history of public health Influence of different environmental factors on exercise How different environmental factors can affect exercise Why bacteria are essential to human survival The benefits of bacteria Will diabetes mellitus become an epidemic? Diabetes mellitus is when the body is unable to produce enough insulin or becomes resistant to it Correlation between a country's HDI and COVID-19 mortality rate HDI stands for Human Development Index, i.e. how much a country is developed considering various factors such as wealth Rising food prices Food deserts and malnutrition Organoids in drug discovery What organoids are, their applications in drug discovery and more The genesis of life What came first: the chicken or the egg? Challenges in endometriosis From underreporting to under-research iPSCs and organoids iPSC stands for induced pluripotent stem cells PCOS and endometriosis These two diseases are very similar, but how are they different? Neutrophil gelatinase-associated lipocalin (NGAL) A biomarker for renal damage Childhood stunting Its issue in developing countries Innovations in the biosciences The biggest ones currently Various health models Understanding health through different stances Medicinal Manuka The benefits of using Manuka honey as medicine The dual role of mitochondria A mechanism for survival, or death? Next

The concept of memory erasure is huge and complex Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Can you erase your memory? 09/07/25, 13:31 Last updated: Published: 23/11/23, 11:08 The concept of memory erasure is huge and complex What is memory? Our brain is a wiggly structure in our skull, made up of roughly 100 billion neurones. It is a wondrous organ, capable of processing 34 gigabytes of digital data per day, yet being able to retain information, and form memory – something that many would argue, defines who we are. So.. what is memory? And how does our brain form them? Loosely defined, memory is the capacity to store and retrieve information. There are three types of memory: short-term, working, and long-term memory (LTM). Today, we will be focusing on LTM. In order to form LTM, we need to learn and store memory. This follows the process of encoding, storage, retrieval, and consolidation. In order to understand the biochemical attributes of memory in our brain, a psychologist, Dr Lashley, conducted extensive experiments on rats to investigate if there were specific pathways in our brain that we could damage to prevent memory from being recalled. His results showed that despite large areas of the brain being removed, the rats were still able to perform simple tasks ( Figures 1-2 ). Lashley’s experiment transformed our understanding of memory, leading to the concept of “engrams”. Takamiya et al., 2020 defines “memory engrams” as traces of LTM consolidated in the brain by experience. According to Lashley, the engrams were not localised in specific pathways. Rather, they were distributed across the whole of the brain. Can memory be erased? The concept of memory erasure is huge and complex. In order to simplify this, let’s divide them into two categories: unintentional, and intentional. Let’s take amnesia for example. This is a form of unintentional memory ‘erasure’. There are two types of amnesia: retrograde amnesia, and anterograde amnesia. Retrograde amnesia is the loss of memory that was formed before acquiring amnesia. On the other hand, anterograde amnesia is the inability to make new memories since acquiring amnesia. Typically, a person with amnesia would exhibit both retrograde, and anterograde amnesia, but at different degrees of severity ( Figure 3 ). Can we ‘erase’ our memory intentionally? And how would this be of use to us? This is where things get really interesting. Currently, the possibility of intentional memory ‘erasure’ is being investigated in patients for the treatment of post-traumatic stress disorder (PTSD). In these clinical trials, patients with PTSD are given drugs that block these traumatic memories. For example, propranolol, an adrenergic beta receptor blocker impairs the acquisition, retrieval, and reconsolidation of this memory. Incredible, isn’t it? Although this is not the current standard treatment for PTSD, we can only imagine how relieving it would be for our fellow friends who suffer from PTSD if their traumatic memories could be ‘erased’. However, with every step ahead, we must always be extremely cautious. What if things go wrong? We are dealing with our brain, arguably one of the most important organs in our body after all. Regardless, the potential for memory ‘erasure’ in treating PTSD seems both promising and intriguing, and the complexities and ethical considerations surrounding such advancements underscore the need for careful and responsible exploration in the realm of neuroscience and medicine. Written by Joecelyn Kiran Tan Related articles: Synaptic plasticity / Boom, and you're back! (intrusive memories) / Sleep and memory loss Project Gallery

Launched in 2021, James Webb Space Telescope (JWST) is an astronomical observatory, designed to explore and observe the universe beyond the capabilities of its predecessor, the Hubble telescope. The JWST has primary mirror of 6.5m in diameter, the largest of any space-based telescope, and its advanced infrared technology, it can observe objects that were previously too faint, old, and distant for the Hubble telescope. Go back Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link James Webb Space Telescope: A Breakthrough in Space Exploration Last updated: 01/03/26 Published: 25/03/23 Launched in 2021, James Webb Space Telescope (JWST) is an astronomical observatory, designed to explore and observe the universe beyond the capabilities of its predecessor, the Hubble telescope. The JWST has a primary mirror of 6.5m in diameter, the largest of any space-based telescope; and with its advanced infrared technology, it can observe objects that were previously too faint, old, and distant for the Hubble telescope. The JWST’s aim is to revolutionise the exploration of the cosmos by studying the earliest galaxies and stars, and to detect light from the first objects that were formed in the universe. In its short deployment time, the JWST has already provided us with fascinating new insights and images of the deep space, pushing the boundaries of our understanding of the cosmos. History of James Webb Space Telescope • 1996: Next Generation Space Telescope project first proposed (8m) • 2001: NEXUS Space Telescope, a precursor to the Next Generation Space Telescope, cancelled • 2002: Proposed project renamed James Webb Space Telescope, (mirror size reduced to 6 m) • 2003: Northrop Grumman awarded contract to build telescope • 2007: Memorandum of Understanding signed between NASA and ESA[72] • 2010: Mission Critical Design Review (MCDR) passed • 2011: Proposed cancellation • 2016: Final assembly completed • 2021: Launch Achievements of James Webb Space Telescope In its short deployment, the JWST has been able to provide some exceptional data, ranging from beautiful pictures of galaxies and nebulas, the first of its kind image of an exo planet and details of exo planets atmosphere. Since its launch, scientists have been discovering galaxies far away and older than ever before, the launch of this observatory has truly made a breakthrough in space exploration. Some of its achievements are explained more in detail below: • To begin with, the JWST has been able to capture some of the most breath-taking and beautiful images of nebulae and galaxies, in both visible light and infrared spectrum. The new pictures have changed the way we had observed these subjects, giving us a deeper insight into the formation stars in these nebulae due to its higher resolutions. Some of the most iconic pictures from the JWST so far have been the pictures of the pillars of creation and the southern ring nebula. • Studying exoplanets have always been a challenge for scientists, as due to their size exoplanets are only visible through analysis of dips in luminance of its host star. But for the first time, the JWST using its infrared spectrometer and primary lens, was able to capture an image of an exoplanet directly. • During its observations, the JWST has been able to study and explore many star systems and in some cases, the exoplanets as well- going as far as studying their atmospheres in some detail, giving the research teams an insight into what these worlds may look like. • The JWST, while observing the deep space, has been able to capture the oldest galaxies known to mankind, dated as old as 13.4 billion years, 350 million years after the Big Bang. Future of Space Exploration and JWST The launch of the JWST marks a significant milestone in the field of space exploration. Not only has it opened up a new era of scientific discovery, but it has also introduced a new era for large space structures. The JWST, being the first self-assembling telescope launched in space, has proven that the only viable option for launching such a massive instrument is to make it segmented and assemble it in orbit. As we move forward, the ability to launch large structures in space that can be reassembled will undoubtedly lead to even more significant discoveries. With 6000 hours allocated for different observation missions, the JWST will enable researchers to work towards solving more of the unanswered questions regarding the cosmos. From deep space observation to exoplanet analysis, the possibilities are endless. Written by Zari Syed Related article: Lonar Lake

The same condition after all? Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder 26/04/26, 14:06 Last updated: Published: 20/01/24, 11:38 The same condition after all? Practice and progress in rheumatology The relationship between hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) has been hotly debated in recent years, with research being published on a near-constant basis attempting to establish a valid symptomatological or causalogical difference between the two disorders. Now, a paper by Ritelli et al. (2022) threatens to end the savage cycle for all. Using RNA sequencing techniques and immunofluorescence, Ritelli et al. found identical gene expression and cellular characteristics in dermal biopsies from those with both conditions. Through immunofluorescence of biopsies from 20 women with hEDS, 16 women and 4 men with HSD and 40 controls, it was found that the shape and components of the extracellular matrix were greatly different in those with HSD/hEDS in comparison to those in the healthy control group. Abnormalities were discovered in the expression of cadherin-11, snail1, and αvβ3, α5β1 and α2β1 integrins. Integrins mediate the connections between the cell cytoskeleton and extracellular matrix to ensure they stay together, cell-to-cell adhesion is initiated by cadherin-11, and snail1 is localised close to the cyclin-dependent kinase inhibitor 2B (CDKN2B) gene. Snail1 can activate CDKN2B gene products when Snail1 is overexpressed to the point of reaching the general localisation of the CDKN2B domain. This demonstrates that there may be a similar causative link between the widespread inflammation and chronic pain in HSD/hEDS and rheumatoid arthritis. Li et al. (2021) proved that the polarisation of macrophages (white blood cells which destroy foreign products) was carefully controlled by the CDKN2B-AS1/ MIR497/TXNIP axis- the increased activation of which in rheumatoid arthritis catalyses the excessive polarisation of macrophages, which causes the macrophages to attack healthy cells. In rat studies published by Tan et al. (2022), it was found that rats with diabetes and induced sepsis experienced greater intestinal injury that control rats without any medical pathology who experienced induced sepsis. This was demonstrated to be due to interruptions in the miR-3061/Snail1 communication pathway. Research on this phenomenon in humans may elucidate the relevance of snail1 overproduction in hEDS/HSD sufferers to their complex gastrointestinal symptoms. If this pathway works similarly in human models of sepsis or localised GI infection, it may intimate that snail1 overproduction is responsible for the hyperpolarisation of macrophages in response to foreign product detection, which may cause immunological damage in the intestines. However, the relevance of this study to hEDS/HSD should be considered questionable until further human research into this avenue has been completed. The result of this research is that academia can potentially derive a genetic cause of the complex phenotypes demonstrated by sufferers of hEDS/HSD. This can be achieved by visualising the human genome, and testing genes like those above, or those implicated in modulating the activity of the genes above. Given this, the 2025 symposium discussed whether HSD and hEDS should be considered separate at all, with discussions around potentially reclassifying or merging them in the future, to improve access to care to patients. Written by Aimee Wilson Related articles: Ehlers-Danlos syndrome / Types of movement Project Gallery

The role of honesty Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Behavioural Economics I 31/10/25, 12:46 Last updated: Published: 24/01/24, 21:37 The role of honesty This is article no. 1 in a series on behavioural economics. Next article: The endowment effect . In the classical realm of economic theory, consumers are said to be utility maximisers. These economic agents will always prefer a situation where they can increase their utility (a measure of well-being or happiness) and will achieve this by any means necessary. Given the opportunity, economic agents will take advantage of others and abuse their power, and although this can be true in many aspects of life, in this article we will explore why people are intrinsically honest, defying classical economic theory, giving a brief insight into how we can explain economic behaviour through the power of behavioural economics. ‘Lost Wallets’ In an effort to measure civic honesty around the globe, Cohn et al. devised a comprehensive study to measure whether people's own material incentives were able to overpower their innate sense of honesty and altruism all together. By distributing over 17,000 ‘lost wallets’ in over 40 countries, Cohn et al. were able to surprisingly prove that people are more honest than we take each other to be. The experiment was simple but comprehensive. A group of people in many different countries would hand in a ‘lost’ wallet to a desk in public areas, for example at a hotel desk or at a library. The wallet contained three business cards - a way to contact the owner, a grocery list, and a key to make it seem more legitimate. Another important detail was that the wallets were transparent, so the receiver did not have to open the wallet to see its contents. The reason why this is important is because some wallets contained money in them, and we wanted to see if this impacted the decision to hand the wallets in or not. In classic economic theory, we would expect that wallets with money in them would not be returned, but instead the receiver would take the money freely. They may be more inclined to return the wallet without money as there would be little benefit in keeping them. However, in real life, this could not be any further from the truth. In 38/40 of the countries, lost wallets were handed back more often when they contained money. Civic honesty was found to be statistically higher when the wallets were not empty. So why are people more likely to hand back their wallets when they contain money? Surely that’s counterintuitive? Well, in fact, one strong explanation is that people value honesty due to their own self-image. If we take the money, our own view of our perfect self becomes threatened, so that the psychological effect of taking the money is greater than the money’s value itself. Similarly, when the wallet contains only business cards, the receiver cannot see any intrinsic value in the wallet. The psychological value of handing the wallet back is now far less worth the effort of making contact with the owner. We disregard the wallet before we even know its contents. Another interesting fact is that when there is a big money condition (7x what was used initially), we find that people are even more likely to report the missing wallet. One explanation may be that with a greater stake, there is also a greater psychological reward for handing the wallet back. When doing an act of kindness as simple as this, people often feel good about themselves, boosting their own ego, and this could be perceived to be greater than the value of their wallet. If the combination of threatened self-image with the positive psychological value of returning the item is much greater than the monetary value of the ‘lost wallet’, then people are likely to return the wallet. In fact, the study showed that over 70% of the wallets were returned when it contained a substantial sum of money. ‘Dice in a Cup’ The second study that I wish to use to describe the effect honesty has on society, is one that involves an extremely simple setup. There is a benefit to having simple experiments in a lab setting. When people volunteer to participate in a lab-controlled experiment, they realise they are being watched (unlike with the previous experiment, which was performed on unsuspecting subjects). This often means that people put in fake answers—the answers they think we wish to hear—which aren’t useful to us. The way we get around this is by putting incentives in place and encouraging people to act the way they would in real life and by ensuring that the experiment is simple, there is no chance that a subject could misinterpret the rules of the experiment. The die-in-the cup experiment run by Gachter and Schulz did just that. Subjects were told to enter a room, and in the middle of the room sat a table with a die placed on top. The subjects were instructed before they entered the room to roll the die twice and then report the first roll of the die only. The number they reported then corresponded to a payout of the following: 1 = £1, 2 = £2... 5 = £5, and 6 = £0. (The pay-out for different countries were in their corresponding currency of equivalent value.) The aim of this experiment is to examine the amount of honesty in a society, and in this paper, they compared this with the presence of rule violations across different societies and looked for a relationship. They discovered that the inhabitants of wealthier countries are more honest on average. In classical economics, if everyone was ‘rational’, they would lie to get the maximum payout every time. This would give an average payout of £5. On the other hand, if everyone was completely honest, the average payout would be £2.50. In the experiment, the mean payout across all countries was around £3 (around £2.90 for the richer nations and up to as high as £4 for the poorer nations). What this tells us is that people are dishonest, but not fully dishonest. One possible explanation is that people would ‘justify dishonesty’. By choosing the higher of the two rolls, people feel less bad about lying completely and bend the rules in their favour. Another explanation is that people take the second-best outcome. In the fear of people being suspicious of them, subjects may decide to say 3 or 4 instead of 5 if, for example, they rolled a 1. But why don’t people lie and say they get a 5 every time? One theory is that people’s desires conflict with their perception of an honest self-image. Like with the lost wallets experiment, people feel guilty by lying completely, but by changing the rules slightly or not taking the highest payout, the benefit of lying is greater than any negative self-perception as in their eyes, they are not lying completely. People are only as dishonest as they can be whilst maintaining a ‘honest’ self-image. So, as we have shown, the foundation of economics can indeed fall short. The basis that people are utility maximisers is not necessarily true in all circumstances, such as when maximising utility violates self-perception. However, this is not to say that we have disproved all of economics. Economics provides an insight into how people and systems in society interact in an ideal setting, which is still beneficial for understanding what a policy is needed to achieve, but behavioural economics can be used to develop the policy further so that its implementation is more seamless. To learn even more about the developments in this ongoing discipline, be sure to follow Scientia News on social media and don’t forget to look out for Part 2 in this new 4-part series discussing the realm of behavioural economics! Written by George Chant Related article: Mathematical models in cognitive decision-making REFERENCES Alain Cohn et al., Civic honesty around the globe. Science 365,70-73(2019) Gächter , S., Schulz, J. Intrinsic honesty and the prevalence of rule violations across societies. Nature 531 , 496–499 (2016) Project Gallery

Not getting enough sleep can increase the risk of developing Alzheimer’s Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Sleep less…remember less: the hidden link between sleep and memory loss Last updated: 10/07/25, 18:27 Published: 17/04/25, 07:00 Not getting enough sleep can increase the risk of developing Alzheimer’s People often don’t get enough sleep for a variety of reasons, ranging from intentional choices like work or study demands (because who needs sleep when you’ve got deadlines, right?), to the growing concern with screen time (a.k.a. the “I’ll just watch one more episode” syndrome), and of course, procrastination (where your brain convinces you that 3 a.m. is a great time to suddenly get productive). But it’s not all fun and games—serious issues like insomnia, sleep apnoea, family responsibilities, or even shift work can also interfere with rest. Sleep disorders are increasingly common, with around one in three people in the UK affected, and they’re particularly prevalent among the elderly. However, not getting enough sleep can increase the risk of developing Alzheimer’s disease (AD). How do sleep disorders impact Alzheimer’s disease? Insomnia is characterised by difficulty falling asleep or staying asleep, which can lead to prolonged fatigue and memory issues. As shown in Figure 1 , people with insomnia tend to have some similarity in markers as those with Alzheimer’s disease, such as an increased level of Aβ and tau proteins in the brain. This is primarily because a lack of sleep prevents the effective removal of harmful products from the brain – this accumulation increases a person’s risk of AD. A plethora of experimental studies on humans and animals have shown that lack of sleep can lead to increased circulating levels of TNF-α and the gene resulting in more TNF-α secretion. This pro-inflammatory cytokine exacerbates AD pathology because neuroinflammation can lead to dysfunction and cell death, which are key markers of AD. Other pro-inflammatory cytokines, like IL-1, have been found to be relevant in the link between sleep deprivation and AD. Overexpression of IL-1 in the brain leads to abnormal changes in nerve cell structures especially relating to Aβ plaques. This highlights IL-1’s key role in plaque evolution and the synthesis of Amyloid Precursor Protein, which promotes amyloid production that eventually results in AD pathology. What type of sleep can impact one’s risk of Alzheimer’s disease? Studies using more objective measures, like actigraphy (which tracks sleep-wake activity), found that sleep quality (sleep efficiency) is more important than total sleep time. For example, women with less than 70% sleep efficiency were more likely to experience cognitive impairment. Increased wakefulness during the night also moderated the relationship between amyloid deposition (a hallmark of AD) and memory decline. Uncertainties… However, it remains unclear whether poor sleep directly causes AD or if the disease itself leads to sleep disturbances. Some studies suggest a bidirectional relationship. Aging itself leads to poorer sleep quality, including reduced sleep efficiency, less slow-wave sleep (SWS), and more frequent awakenings. Sleep disorders like obstructive sleep apnoea, insomnia, and restless legs syndrome also become more common with age. What are the next steps? The good news is that many sleep disorders, including insomnia, are manageable, and improving sleep quality could be a simple yet powerful way to reduce Alzheimer’s risk. Additionally, early diagnosis and treatment of conditions like sleep apnoea and insomnia may help slow or even prevent neurodegenerative changes. s researchers continue to explore the intricate relationship between sleep and Alzheimer’s, one thing is clear: getting a good night’s sleep isn’t just about feeling refreshed. It is a crucial investment in long-term brain health. Written by Blessing Amo-Konadu Related articles: Overview of Alzheimer's / Hallmarks of Alzheimer's / CRISPR-Cas9 in AD treatment / Memory erasure / Does insomnia run in families? REFERENCES Lucey, B. (2020). It’s complicated: The relationship between sleep and Alzheimer’s disease in humans. Neurobiology of Disease , [online] 144, p.105031. doi: https://doi.org/10.1016/j.nbd.2020.105031 . NHS (2023). Insomnia . [online] www.nhsinform.scot . Available at: https://www.nhsinform.scot/illnesses-and-conditions/mental-health/insomnia/ . Pelc, C. (2023). Not getting enough deep sleep may increase the risk of developing dementia . [online] Medicalnewstoday.com . Available at: https://www.medicalnewstoday.com/articles/not-getting-enough-deep-sleep-may-increase-dementia-risk#Clarifying-the-link-between-sleep-aging-and-dementia-risk [Accessed 22 Dec. 2024]. Sadeghmousavi, S., Eskian, M., Rahmani, F. and Rezaei, N. (2020). The effect of insomnia on development of Alzheimer’s disease. Journal of Neuroinflammation , 17(1). doi: https://doi.org/10.1186/s12974-020-01960-9 . Project Gallery

And can we overcome them? Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Challenges in Modern Day Chemistry 04/04/26, 16:39 Last updated: Published: 24/02/24, 22:09 And can we overcome them? Chemistry is often called the "central science" because it connects everything in the natural world. It is the foundation for how we understand life and is essential for solving the massive problems facing humanity today. In recent years, chemistry has changed significantly as top researchers push the boundaries of technology. However, this progress is met with a series of complex, overlapping challenges that require creative and completely new solutions. This article explores the most difficult hurdles currently facing the world of modern chemistry. Sustainability and the Imperative of Green Chemistry The biggest challenge for modern chemistry is the urgent need for environmental sustainability. For a long time, the chemical industry has been a major contributor to pollution and the loss of natural resources. Because of this, there is a desperate need to create "greener" and safer chemical processes. Green chemistry is a leading movement focused on designing products that avoid using or creating hazardous materials. Researchers in this field are working hard to find non-toxic alternatives and energy-efficient methods to reduce the damage caused by chemical work. Energy Storage and Conversion at the Frontier As the world demands more renewable energy, like solar and wind power, the need for better ways to store and convert that energy has become incredibly urgent. Chemistry is at the heart of developing advanced batteries, fuel cells, and supercapacitors. However, scientists are still struggling with how to make batteries hold more power, last longer, and cost less to produce. To solve this, a massive effort is underway to find brand-new materials and invent better ways to manage the chemical reactions that store electricity. Drug Resistance as a Crescendoing Predicament The rise of "superbugs"—bacteria that antibiotics can no longer kill—is a growing crisis in medicine. As germs continue to evolve, chemists face the massive task of constantly inventing new antibiotics and antiviral drugs. At the same time, the move toward "personalized medicine" requires new ways to design drugs that are tailored to a specific person’s body. The ultimate goal is to find a way to stop drug resistance while also getting rid of dangerous side effects, which is one of the most difficult puzzles in chemistry today. Ethical Conundrums and the Regulatory Labyrinth As chemistry continues to move forward, the ethical and legal questions surrounding it become more complicated. Issues like who owns a discovery, how to innovate responsibly, and how to prevent chemical knowledge from being used for harm require careful thought and strict ethical rules. Finding the right balance between pushing for scientific breakthroughs and being a responsible protector of those discoveries is a constant challenge for the chemistry community. In conclusion... Modern chemistry is a fast-moving field that drives innovation in almost every industry while tackling global problems. However, it must overcome its own obstacles, from environmental responsibility and drug resistance to complex ethical dilemmas. Success will require experts from different fields to work together, use their imaginations, and commit to using their power for good. As we continue to learn more about the world of atoms and molecules, solving these problems is the only way to ensure a sustainable and successful future for everyone. Written by Navnidhi Sharma Related article: Green Chemistry Project Gallery

Key facts Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Apocrine carcinoma: a rare form of breast cancer 22/04/25, 14:13 Last updated: Published: 05/09/24, 10:20 Key facts This is article no. 7 in a series on Rare Diseases. Next article: Pseudo-Angelman Syndrome . Previous article: Neuromyelitis optica . Apocrine carcinoma (AC) is a rare form of breast cancer, accounting for approximately 1-4% of all breast cancer cases worldwide. It affects a wide range of patients from 19 to 92 years of age, with the reported mean age varying from 53 to 62 years. AC of the skin - primary cutaneous apocrine carcinoma - is the only other known cancer that arises from apocrine cells. This is a very rare cancer with limited research. AC is commonly classified into two subtypes: triple-negative AC (TNAC) and HER2+ AC. Another receptor not included in the ‘triple negative’ name is the androgen receptor (AR). A ‘pure’ apocrine carcinoma is ER-negative, PR-negative, but AR-positive. Among triple negative ACs, ones that are AR-positive have a better prognosis. AC is often associated with triple-negative breast cancers (TNBC), meaning that it does not express oestrogen receptors (ER) and progesterone receptors (PR), and produces very little to no HER2– all of which play key roles in the reproductive system. AC arises from apocrine metaplastic cells that are commonly located in the lobules of the breast. This disease can be aggressive and can metastasise to the lymph nodes and distant organs (eg. lungs, liver, and bone). What makes AC different is the appearance of cells which have abundant granular eosinophilic or cytoplasm with fine empty vacuoles. Despite its rarity, focal apocrine differentiation is relatively common (reported in approximately 60% of not otherwise specified [NOS] invasive ductal carcinoma) and shows clinical presentation and radiographic findings similar to that of invasive ductal carcinoma NOS. TNBCs are generally aggressive and present a poor prognosis. However, studies show apocrine breast cancer to have a better prognosis and low proliferative nature, despite its poor response to neoadjuvant chemotherapy. Treatment of AC may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy. The problem with TNACs is that therapies targeting the hormone receptors are ineffective. Conversely, targeted therapy is seen to work relatively well with HER2-positive ACs despite them being more aggressive than TNACs. ACs can be diagnosed through a series of tests—usually a mammogram, ultrasound, biopsy, and finally immunohistochemistry. The latter makes it possible to know the status of the ERs and PRs. As with most breast cancers the earlier the detection and treatment implementation, the better the prognosis for the patient. ACs can be hard to diagnose due to its rarity and non-specific presentation. AC has a low proliferative nature, which is shown in its low Ki-67 index. Ki-67 has a higher presentation in cells that have a high division rate. Slower division rates result in slower growth rates of the tumour, and may imply that there is a better prognosis. This could be one of the reasons why apocrine triple-negative breast cancers have a better prognosis than other types of TNBCs. There is promise in the future for AC, however this is not without its challenges. Due to its rarity there are limited patients to participate in clinical trials which are essential in new treatment development. Written by Henrietta Owen & Sherine A Latheef Related article: Epitheliod hemangioendothelioma REFERENCES Apple, S.K., Bassett, L.W. and Poon, C.M. (2011) ‘Invasive ductal carcinomas’, Breast Imaging, pp. 423–482. doi:10.1016/b978-1-4160-5199-2.00022-9. Bcrf (2024) Types of breast cancer: BCRF, Breast Cancer Research Foundation. Available at: https://www.bcrf.org/blog/types-of-breast-cancer/ (Accessed: 05 June 2024). Hu, T. et al. (2022) ‘Triple-negative apocrine breast carcinoma has better prognosis despite poor response to neoadjuvant chemotherapy’, Journal of Clinical Medicine, 11(6), p. 1607. doi:10.3390/jcm11061607. Suzuki, C., Yamada, A., Kawashima, K., Sasamoto, M., Fujiwara, Y., Adachi, S., Oshi, M., Wada, T., Yamamoto, S., Shimada, K., Ota, I., Narui, K., Sugae, S., Shimizu, D., Tanabe, M., Chishima, T., Ichikawa, Y., Ishikawa, T., & Endo, I. (2023). Clinicopathological Characteristics and Prognosis of Triple-Negative Apocrine Carcinoma: A Case-Control Study. World Journal of Oncology, 14(6), 551-557. Vranic, S., Feldman, R. and Gatalica, Z. (2017) ‘Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers’, Bosnian Journal of Basic Medical Sciences, 17(1), pp. 9–11. doi:10.17305/bjbms.2016.1811 Xiao, X., Jin, S., Zhangyang, G., Xiao, S., Na, F. and Yue, J. (2022). Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses. Gland Surgery, 11(6), pp.1037–1046. doi:https://doi.org/10.21037/gs-22-248. Project Gallery

Linking a country's HDI with its COVID-19 mortality rate Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Correlation between wealthy countries and COVID-19 mortality rate 09/03/26, 08:30 Last updated: Published: 24/08/23, 16:20 Linking a country's HDI with its COVID-19 mortality rate Investigation title: Could there have been a correlation between very rich countries and COVID-19 mortality rate? Investigation period: December 2019- November 2020 (Approx. 1 year) Background The World Health Organisation (WHO) were first alerted about coronavirus on the 31st December 2019, by a lot of pneumonia cases in Wuhan, China that has a population of 11 million. Furthermore, by 15th January 2020 there were precisely 289 cases recorded in countries such as: Thailand, Japan, S.Korea, and other places in China. And of the original cases there were 6 deaths, 51 severe cases - 12 of which were in critical condition. Meanwhile, the virus responsible for the cases was isolated and had its genome mapped, and was shared on 12th January. HDI represents the measurement of development. This is a composite of Gross National Income (GNI) per capita, mean years of education and life expectancy at birth, to measure the development of a country. It is calculated between a scale of 0 (least developed) to 1 (most developed) and all its values are to 3 significant figures. HDI values of 2019 and countries of HDI greater than 0.800 were used, as these are all regarded as very high HDI-countries so were in the scope of this investigation. Therefore, this research aimed to determine the impact of human development on the number of mortalities caused by SARS-CoV-2; where human development is measured by HDI, and the number of mortalities per hundred thousand from December 2019 to November 2020. Method Stratified sampling produced 12 countries, in descending order of HDI value: - Australia, Netherlands, UK, Austria, Spain, Estonia, UAE, Portugal, Bahrain, Kazakhstan, Romania, Malaysia See Table 4 . Results See Chart 2 . r= 0.321 (3 s.f.) – Pearson’s test ∴ There is a moderate positive linear correlation between HDI and mortality rate due to SARS-CoV-2 per 100,000. Further stats testing- Spearman’s Rank ∑D^2 = 216 n = 12 Rs = 1 - (6 ∑D^2 )/ n(n^2 – n) = 1 - (6 x 216) 1584 = 0.182 (3 d.p.) Rs = 0.245 ＜ Critical Value (0.0.587591) ∴ There is no correlation between HDI and mortality rate due to coronavirus per 100,000. Conclusion The null hypothesis was accepted: there is no correlation between a country’s HDI and its mortality rate due to SARS-CoV-2. A biogeographical reason for this is that the more developed countries (such as those in my investigation- for example, the UK) have a higher level of immigration from latitudes closer to the equator, therefore there is a section of their society with increased susceptibility to SARS-CoV-2 due to vitamin D deficiency. It is known that low vitamin D levels have a negative impact on immune function and that low vitamin D levels are common in the immigrant population. Therefore, it is likely that there is a link between vitamin D deficiency and mortality rate per 100,000, however this could be overstated due to confounding factors such as socioeconomic status, residence and employment. This would explain why countries at higher latitudes like the Netherlands have higher mortality rates per 100,000 (41.80) which is the third highest HDI-country in this investigation. Another explanation for this non-correlation could be that the less developed countries could be more used to dealing with a pandemic, or stress on a healthcare system, due to previous experience. For example, after the SARS outbreak, many countries decided to prepare in case of a pandemic, however some large HDI-countries such as the UK chose not to and even ignored other warnings on the effects of a pandemic (like the exercise signs simulation). Moreover, studies have shown that as a very high HDI-country becomes more developed, its healthcare system continues to develop until it reaches a peak where its effectiveness is undermined by economic benefit or interest. This would explain why the UK had a death rate of 342 per 100,000 and a total death count of around 232,422 (as of early 2026), and as of 2024/25, the UK recorded higher-than-expected death rates compared to other countries. Implications Since there is no correlation between a country’s HDI index and its mortality rate of COVID-19, this may apply to other diseases that became pandemics such as 1918’s Spanish Flu, or more recent ones like the SARS outbreak in the early 21st century. As for tropical diseases (malaria, dengue, chikungunya and others) and other illnesses such as the common cold and the flu, these diseases present in only certain geographies. This means that the countries with these ailments will be of a similar HDI and economical status; therefore there would be a correlation between a country’s HDI index and its mortality rate of these diseases, to a certain extent. Investigation conducted and written by Roshan Gill Tables, charts, stats and calculations by Roshan Gill Summary by Manisha Halkhoree ‘Implications’ section by Manisha Halkhoree Related articles: Causality vs correlation / Impacts of global warming on dengue fever / Global Health Injustices (series) Project Gallery